title: High on treatment platelet reactivity.
abstract: The addition of clopidogrel to aspirin for patients undergoing percutaneous coronary intervention (PCI) had significantly reduced cardiovascular events. However, despite dual antiplatelet therapy ischaemic events still occur, especially stent thrombosis, which is associated with a high mortality rate. Inter-individual response to clopidogrel is highly variable. It was shown that 4-46% could be considered as high on treatment platelet reactivity (HTPR). Recent studies had demonstrated a relationship between HTPR and ischaemic events in the setting of PCI. Actually the assessment of platelet reactivity in routine practice and its interpretation to make a decision is a debatable issue.
authors: Department of Cardiology, Centre Hospitalier Universitaire Nord, Marseille 13015, France. aitmokhtar1@yahoo.fr
authors: Omar
authors: O
authors: Ait-Mokhtar
authors: Laurent
authors: L
authors: Bonello
authors: Saida
authors: S
authors: Benamara
authors: Franck
authors: F
authors: Paganelli
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D004347:Drug Interactions; D004351:Drug Resistance; D006801:Humans; D017202:Myocardial Ischemia / Q000097:blood / Q000150:complications / Q000628:therapy; D015539:Platelet Activation / Q000187:drug effects*; D010979:Platelet Function Tests / Q000379:methods; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D015607:Stents; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D016861:Cyclooxygenase Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin